Janssen Search
Search results
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU
Jan 24, 2024 United States Clinical and real-world evidence data support treatment with ERLEADA ® (apalutamide) and niraparib plus abiraterone acetate given with prednisone in patients with prostate cancer Additional updates will be presented on ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease
Jun 21, 2024 Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction, consistent with intravenous (IV) ...
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
Aug 23, 2024 Belgium First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR 3 alterations Approval based on THOR results, showing 36 percent ...
Dmitri Talantov, M.D.
Dmitri Talantov, M.D. SENIOR MEDICAL DIRECTOR, JCI Dr. Talantov is a medical leader with Janssen Clinical Innovation based in California. He is responsible for development of novel clinical trial models, including direct-to-patient and hybrid trials and ...
Megha Reddy
MEGHA REDDY HEAD OF STRATEGY WORLD WITHOUT DISEASE ACCELERATOR As Head of Strategy for the World Without Disease Accelerator (WWDA), Megha leads the overall WWDA strategic planning, including the development of short- and long-term goals and objectives. ...
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024
May 30, 2024 NEW BRUNSWICK, N.J., May 30, 2024 – Johnson & Johnson (NYSE: JNJ) today announced William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September ...
Getting into the Game: How pharmas are thinking about the microbiome for drug development
Getting into the Game: How pharmas are thinking about the microbiome for drug development Jan 06, 2017 Article Block Text: BioCentury – May 9, 2016 Redirect URL: http://www.biocentury.com/biotech-pharma-news/products/2016-05-09/how-pharmas-are-thinking ...
Patient Engagement
Patient Engagement Dec 12, 2019 Janssen partners directly with patients and caregivers as we develop medicines, improve clinical trials, and create educational materials and support programs. Article Block Text: Janssen partners directly with patients ...
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Mar 18, 2024 Czech Repubic Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab PRAGUE, CZECH REPUBLIC (March 18, 2024)-- Johnson & ...
Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
Jun 03, 2024 Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data CHICAGO (June 3, 2024) – Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 ...